Further investigation revealed that inhibition of ADRB2 impedes lung fibrosis by reducing TGF-β/SMAD signaling activity through the acceleration of phos-SMAD2/3 proteasome degradation. Here, SMAD2 is linked to pulmonary fibrosis.